Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmacokinetics of intravenous

F. Bree, G. Houin, J. Barre, J. L. Moretti, V. Wirquin, and J.-P. Tillement, Pharmacokinetics of intravenously administered 125I-labelled human alpha-1-acid glycoprotein, Clin. Pharmacokinet, 11, 336-342 (1986). [Pg.144]

Bright JE, Marrs TC. 1988. Pharmacokinetics of intravenous potassium cyanide. Hum Toxicol 7 183-186. [Pg.240]

Donovan JL, DeVane CL, Malcolm RJ, Mojsiak J, Nora-Chiang C, Elkashef A Taylor RM (2005). Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers. Clinical Pharmacokinetics, 44, 753-65... [Pg.154]

Marked inter-patient variability exists in the pharmacokinetics of intravenous anaesthetics. Factors that can influence drug disposition include the degree of protein binding, the efficiency of the hepatic and renal clearance systems, physiological changes with ageing, disease states, site of operation, body temperature, and drug interactions (premedicants, volatile anaesthetics). [Pg.77]

Gyr, E., R. Brenneisen, D. Bourquin, T. Lehmann, et al., Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmoiphine in opioid dependents, a two-patient pilot study within a heroin-assisted treatment program, Int. J. Clin. Pharmacol. Ther., 38(10), 486—491, 2000. [Pg.59]

Burke, J. T., W. A. Virgin, R. J. Sherertz, K. L. Sanders, M. R. Blum, and F. A. Sarubbi. 1982. Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function. J. Pharmacokin. Biopharrrl0 601-614. [Pg.461]

Gerber, N., Mays, D. C., Donn, K. H., et al. Safety, tolerance and pharmacokinetics of intravenous doses of phosphate-3-ester of hydroxymethyl-5,5-diphenylhydantoin, a new prodrug of phenytoin. J. Clin. Pharmacol. 28 1023-1032, 1988. [Pg.104]

Sanders, A. B., and Moore, J. G. Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant-rate infusions. Chronobiol. Int. 8 267—276, 1991. [Pg.426]

Ko H, Cathcart KS, Griffith DL, et al. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. Antimicrob Agents Chemother 1989 33 356-361. [Pg.200]

Jonas MM, Linton RAF, O Brien TK, Band DM, Linton NWF, Kelly F, Burden TJ, Chevalier SFA, Thompson RPH, Birch NJ, Powell JJ. The pharmacokinetics of intravenous hthium chloride in patients and normal volunteers. J Trace Microprobe Techn 2001 19 313-20. [Pg.178]

McDonnell CG, Harte S, O DriscollJ, O Loughlin C, Van Pelt FD, Shorten GD. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia 2003 58 899-904. [Pg.426]

Note. For a review of the pharmacokinetics of intravenous anaesthetic agents see P. Duvaldestin, Clin. Pharmacokinet., 1981,6,61-82. [Pg.331]

Lacy SA, Hitchcock MJM, Lee WA, Tellier P, Gundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 1998 44 97-106. [Pg.246]

Overholser BO, Kays MB, Lagvankar S, Goldman M, Mueller BA, Sowinski KM. Pharmacokinetics of intravenously administered levofloxacin in men and women. Pharmacotherapy 2005 in press. [Pg.334]

Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. A rationale for treatment. Contrib Nephrol 1989 76 112-21. [Pg.498]

Olsen KM, Rebuck JA, Weidenbach T, Fish DN. Pharmacokinetics of intravenous trovafloxacin in critically ill adults. Pharmacotherapy 2000 20(4) 400-4. [Pg.48]

Tsutsumi K, Kotegawa T, Kuranari M, Otani Y, Morimoto T, Matsuki S, Nakano S. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. J Clin Pharmacol 2002 42(10) 1159-64. [Pg.673]

The pharmacokinetics of intravenous ciprofloxacin have been studied in intensive care unit patients during continuous venovenous hemofiltration (n — 5) or hemo-diafiltration (n — 5) (67). Ciprofloxacin clearance was not altered. A dosage of 400 mg/day was sufficient to maintain effective drug plasma concentrations in patients undergoing continuous renal replacement therapy. [Pg.785]

Misiak PM, Eldon MA, Toothaker RD, Sedman AJ. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin. J Clin Pharmacol 1993 33(l) 53-6. [Pg.1407]

Gajjar DA, LaCreta FP, Uderman HD, Kollia GD, Duncan G, Birkhofer MJ, Grasela DM. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000 20(6 Pt 2) S49-58. [Pg.1483]

The thrombin inhibitor argatroban had no effect on the pharmacokinetics of intravenous lidocaine 1.5 mg/kg for 10 minutes followed by 2 mg/kg/hour for 16 hours in 12 healthy volunteers the argatroban was given as an intravenous infusion of 2 pg/kg/minute for 16 hours (73). [Pg.2057]

Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol I998 54(7) 56I-5. [Pg.2060]

Corvaia L, Li SC, loannides-Demos LL, Bowes G, Spicer WJ, Spelman DW, Tong N, McLean AJ. A prospective study of the effects of oral probenecid on the pharmacokinetics of intravenous ticarcillin in patients with cystic fibrosis. J Antimicrob Chemother 1992 30(6) 875-8. [Pg.2922]

Rey E, Luquel L, Richard MO, Mory B, Offenstadt G, OUve G. Pharmacokinetics of intravenous salbutamol in renal insufficiency and its biological effects. Eur J Clin Pharmacol 1989 37(4) 387-9. [Pg.3097]

Siber GR, Gorham CC, Ericson JF, Smith AL. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Reviews of infectious diseases. 1982 Mar-Apr 4(2) 566-78. [Pg.373]

Nissenson AR, Wilson C, Flolazo A. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. American journal of nephrology. 1987 7(4) 270-4. [Pg.373]

Conte JE, Jr. Pharmacokinetics of intravenous pentamidine in patientswith normal renal function or receiving hemodialysis. The Journal of infectious diseases. 1991 Jan l 63(1 ) 169-75. [Pg.376]

Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. Journal of Veterinary Pharmacology and Therapeutics 20 355-361... [Pg.119]

Clarke C R, Burrows G E. MacAllister C G et al 1992 Pharmacokinetics of intravenously and orally administered pyrimethamine in horses. American Journal of Veterinary Research 53 2292-2295 Daft B M, Barr B C, Gardner I A et al 2002 Sensitivity and specificity of Western blot testing of cerebrospinal fluid and serum for diagnosis of equine protozoal myeloencephalitis in horses with and without neurologic abnormalities. Journal of the American Veterinary Medical Association 221 1007-1013... [Pg.152]

Wan P Y, Trim C M, Mueller P O 1992 Xylazine-ketamine and detomidine-tiletamine-zolazepam anesthesia in horses. Veterinary Surgery 21 312-318 Waterman A E, Amin A 1992 The influence of surgery and anaesthesia on the pharmacokinetics of pethidine in the horse. Equine Veterinary Journai Suppiement 11 56-58 Waterman A E, Robertson S A, Lane J G 1987 Pharmacokinetics of intravenously administered ketamine in the horse. Research in Veterinary Science 42 162-166... [Pg.309]

Thompson JA, Bloedow DC, Leffert FH. Pharmacokinetics of intravenous chlorpheniramine in children. J Pharm Sci 1981 70 1284-1286. [Pg.251]

See other pages where Pharmacokinetics of intravenous is mentioned: [Pg.686]    [Pg.239]    [Pg.239]    [Pg.392]    [Pg.461]    [Pg.148]    [Pg.345]    [Pg.346]    [Pg.1143]    [Pg.1143]    [Pg.1143]    [Pg.1353]    [Pg.1880]    [Pg.362]    [Pg.87]   


SEARCH



© 2024 chempedia.info